TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 2193996
Drug: Informed group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Informed group (received patient education about drug side effects)
Study: 2193996
Drug: Uninformed group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Uninformed group (no information about drug side effects)
Study: 2193996
Drug: Both groups
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both groups (compliance with therapy)
Study: 2193996
Drug: Both groups
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both groups (results of treatment)
Study: 84951
Drug: Antipyrine (phenazone)
Normalized name: Antipyrine
DrugBank: Antipyrine (DB01435)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antipyrine (phenazone) treatment of mothers from the 38th week of pregnancy
Study: 16751162
Drug: Intrathecal morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrathecal morphine 5 microg/kg
Study: 11074738
Drug: Androstenedione (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Androstenedione (200 mg/d)
Study: 11074738
Drug: Androstenediol (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Androstenediol (200 mg/d)
Study: 8873543
Drug: Simultaneous administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Simultaneous administration of desflurane to both lungs
Study: 8873543
Drug: Topical and
Normalized name: norgestimate and ethinylestradiol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical and nebulized lidocaine, glossopharyngeal and superior laryngeal nerve blocks, transtracheal administration of lidocaine
Study: 8873543
Drug: Systemic infusions
Normalized name: nitroglycerin
DrugBank: Nitroglycerin (DB00727)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Systemic infusions of 2% lidocaine
Study: 26746903
Drug: Referral for
Normalized name: teferrol
DrugBank: Iron polymaltose (DB15763)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Referral for a post discharge medicines use review (MUR) with their regular community pharmacist
Study: 22678319
Drug: Diclofenac 1
Normalized name: diclofenac 18 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diclofenac 1 mg/kg
Study: 22678319
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of diclofenac and ketamine (0.15 mg/kg)
Study: 22678319
Drug: Placebo (100-mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (100-mL isotonic saline)
Study: 7838584
Drug: Ketamine (0.15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketamine (0.15 mg/kg)
Study: 22678319
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of diclofenac and ketamine
Study: 21970545
Drug: Rosiglitazone therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rosiglitazone therapy
Study: 20656674
Drug: Rosiglitazone therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rosiglitazone therapy (excluding RECORD trial)
Study: 20656674
Drug: Rosiglitazone therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rosiglitazone therapy (alternative analysis)
Study: 10765125
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of FU (600 mg/m2/week x 6, followed by a 2-week rest) and LV (500 mg/m2/week x 6 as a 2-hour infusion, followed by a 2-week rest) for 4 cycles (group A)
Study: 10765125
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of FU and LV plus recombinant IFN (3 MU subcutaneously 3 times a week for 1 year) (group B)
Study: 1994661
Drug: High-dose diltiazem
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose diltiazem (mean dose, 329 mg/day)
Study: 8289096
Drug: Comprehensive multidisciplinary
Normalized name: Easy Care First Aid Kit - Comprehensive KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comprehensive multidisciplinary treatment strategy
Study: 8289096
Drug: Comprehensive multidisciplinary
Normalized name: Easy Care First Aid Kit - Comprehensive KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comprehensive multidisciplinary treatment strategy (in intermediate risk subgroup)
Study: 3511404
Drug: High-dose parenteral
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose parenteral 6-methylprednisolone (MP)
Study: 29572124
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg baclofen
Study: 28199679
Drug: DNA/rAd5 vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: DNA/rAd5 vaccine
Study: 16586388
Drug: Rifaximin (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rifaximin (200 mg 3 times daily for 3 days)
Study: 14959882
Drug: 14 percent
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 14 percent hydrogen peroxide gel strip (Crest Whitestrips Supreme)
Study: 9187023
Drug: Low molecular
Normalized name: Low molecular weight heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low molecular weight heparin (LMWH) intravenous (iv)
Study: 9187023
Drug: Low molecular
Normalized name: Low molecular weight heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low molecular weight heparin (LMWH) subcutaneous (sc)
Study: 8387806
Drug: Perindoprilat (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perindoprilat (1 mg over six hours)
Study: 8387806
Drug: Enalaprilat (1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalaprilat (1.5 mg over six hours)
Study: 8387806
Drug: Intravenous placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous placebo (saline)
Study: 3544631
Drug: nadolol 80
Normalized name: nadolol 80 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: nadolol 80 mg/day
Study: 25854500
Drug: ACL conservative
Normalized name: Conserved dopamine neurotrophic factor
DrugBank: HER-902 (DB17948)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACL conservative treatment
Study: 25033066
Drug: Alendronate (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alendronate (40 mg daily for subjects > 50 kg, 20 mg for 30‐50 kg, 10 mg for 20‐30 kg)
Study: 15875530
Drug: Lycopene (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lycopene (30 mg daily for 1 week)
Study: 12885710
Drug: Iron-fortified fish
Normalized name: INFANT FORMULA SMA IRON FORTIFIED CONC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iron-fortified fish sauce (10 mL containing 10 mg Fe as NaFeEDTA)
Study: 11143915
Drug: Harpagophytum 2,610
Approvals — FDA: no, EMA: no, PMDA: no
Description: Harpagophytum 2,610 mg per day
Study: 11143915
Drug: Diacerhein 100
Normalized name: diacetylrhein
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diacerhein 100 mg per day
Study: 28723914
Drug: Dalazatide 30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dalazatide 30 mcg/dose
Study: 28723914
Drug: Dalazatide 60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dalazatide 60 mcg/dose
Study: 26496265
Drug: Pirfenidone (1800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pirfenidone (1800 mg per day) + NAC (1800 mg per day)
Study: 26496265
Drug: Placebo +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo + NAC (1800 mg per day)
Study: 15585770
Drug: Zinc doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zinc doses of 2.2 mg
Study: 15585770
Drug: Zinc doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zinc doses of 5.2 mg
Study: 15585770
Drug: Zinc doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zinc doses of 10.4 mg
Study: 15585770
Drug: Zinc doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zinc doses of 15.2 mg
Study: 15585770
Drug: Zinc doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zinc doses of 20.3 mg
Study: 15585770
Drug: Zinc doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zinc doses of 30.1 mg
Study: 11736882
Drug: UDCA (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: UDCA (50 mg)
Study: 11736882
Drug: CDCA (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: CDCA (600 mg)
Study: 11736882
Drug: Control (nitrendipine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (nitrendipine 10 mg without bile acids)
Study: 7835324
Drug: Raw potato
Approvals — FDA: no, EMA: no, PMDA: no
Description: Raw potato starch (RPS) 50 g
Study: 7835324
Drug: Corn flakes
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corn flakes (CF) 100 g
Study: 7835324
Drug: Hylon VII
Normalized name: factor VII
DrugBank: Coagulation factor VII human (DB13150)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hylon VII high amylomaize starch (HAS) 75 g
Study: 7835324
Drug: Hylon VII
Normalized name: factor VII
DrugBank: Coagulation factor VII human (DB13150)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hylon VII high amylomaize starch (HRA) 25 g
Study: 7835324
Drug: Daily administration
Normalized name: Prevpac 30mg-500mg-500mg Daily Administration Pack
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily administration of RPS for 3 weeks
Study: 7835324
Drug: Daily administration
Normalized name: Prevpac 30mg-500mg-500mg Daily Administration Pack
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily administration of HAS for 3 weeks
Study: 2964327
Drug: Miglitol 50mg
Normalized name: MIGLITOL 50MG TAB
DrugBank: Miglitol (DB00491)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Miglitol 50mg three times daily for 4 weeks
Study: 19675034
Drug: Steroid injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Steroid injection (group B)
Study: 16311070
Drug: Serum digoxin
Normalized name: Digoxin
DrugBank: Digoxin (DB00390)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Serum digoxin concentration (SDC) ≥1.2 ng/ml
Study: 16311070
Drug: Serum digoxin
Normalized name: Digoxin
DrugBank: Digoxin (DB00390)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Serum digoxin concentration (SDC) 0.5-1.1 ng/ml
Study: 16311070
Drug: Serum digoxin
Normalized name: Digoxin
DrugBank: Digoxin (DB00390)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Serum digoxin concentration (SDC) 0.5-1.1 ng/ml in women with EF <35%
Study: 16311070
Drug: Serum digoxin
Normalized name: Digoxin
DrugBank: Digoxin (DB00390)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Serum digoxin concentration (SDC) 0.5-1.1 ng/ml in women with EF ≥35%
Study: 15309451
Drug: Lycopene tablets
Normalized name: lycopene Oral Tablet
DrugBank: Lycopene (DB11231)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lycopene tablets
Study: 11576930
Drug: Treatment with
Normalized name: Campho-Phenique Cold Sore Treatment with Drying Action
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment with supraphysiological doses of folic acid and vitamins B(6) and B(12)
Study: 9244210
Drug: Low-dose ramipril
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose ramipril (0.625 mg daily)
Study: 9244210
Drug: Full-dose ramipril
Normalized name: Ramipril
DrugBank: Ramipril (DB00178)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Full-dose ramipril (1.25 mg titrated to 10 mg/d)
Study: 2244446
Drug: Cimetidine (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cimetidine (200 mg IV)
Study: 2244446
Drug: Famotidine (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Famotidine (20 mg IV)
Study: 30058959
Drug: Rivaroxaban 2.5
Normalized name: rivaroxaban 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rivaroxaban 2.5 mg bid plus acetylsalicylic acid 100 mg
Study: 30058959
Drug: Rivaroxaban 5
Normalized name: Rivaroxaban
DrugBank: Rivaroxaban (DB06228)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Rivaroxaban 5 mg bid
Study: 30058959
Drug: Acetylsalicylic acid
Normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Acetylsalicylic acid 100 mg per day
Study: 28422300
Drug: Atorvastatin LD
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin LD 80 mg
Study: 28422300
Drug: Rosuvastatin LD
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rosuvastatin LD 40 mg
Study: 28422300
Drug: Low-dose statins
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose statins (subgroup analysis)
Study: 26224613
Drug: Autologous conditioned
Normalized name: AUTOLOGOUS CONDITIONED PLASMA
DrugBank: Platelet Rich Plasma (DB19295)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Autologous conditioned plasma (ACP) injections
Study: 23289345
Drug: JCS‐01 focused
Approvals — FDA: no, EMA: no, PMDA: no
Description: JCS‐01 focused ultrasound fat reduction machine treatment on the 1st and 7th days.
Study: 23289345
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group with ultrasound energy turned off during treatments.
Study: 16256784
Drug: Insulin treatment
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin treatment during cardiopulmonary bypass
Study: 10218737
Drug: Mibefradil (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mibefradil (50 mg, titrated to 100 mg)
Study: 10218737
Drug: Enalapril (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalapril (20 mg, titrated to 2 x 20 mg)
Study: 8730975
Drug: Allopurinol 100
Normalized name: allopurinol 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Allopurinol 100 mg
Study: 28608311
Drug: Allopurinol 600
Normalized name: Allopurinol
DrugBank: Allopurinol (DB00437)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Allopurinol 600 mg
Study: 8730975
Drug: Allopurinol 900
Normalized name: Allopurinol
DrugBank: Allopurinol (DB00437)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Allopurinol 900 mg
Study: 1858727
Drug: H influenzae
Normalized name: h influenzae type b
Approvals — FDA: no, EMA: no, PMDA: no
Description: H influenzae b oligosaccharide‐CRM197 conjugate vaccine (3 doses)
Study: 1858727
Drug: H influenzae
Normalized name: h influenzae type b
Approvals — FDA: no, EMA: no, PMDA: no
Description: H influenzae b oligosaccharide‐CRM197 conjugate vaccine (2 doses) followed by H influenzae type b polysaccharide vaccine (1 dose)
Study: 1858727
Drug: H influenzae
Normalized name: h influenzae type b
Approvals — FDA: no, EMA: no, PMDA: no
Description: H influenzae b oligosaccharide‐CRM197 conjugate vaccine (1 dose) followed by H influenzae type b polysaccharide vaccine (2 doses)
Study: 1858727
Drug: H influenzae
Normalized name: h influenzae type b
Approvals — FDA: no, EMA: no, PMDA: no
Description: H influenzae type b polysaccharide vaccine (as a second dose)
Study: 30794252
Drug: Microtextured implants
Approvals — FDA: no, EMA: no, PMDA: no
Description: Microtextured implants with microgrooved collar design
Study: 30794252
Drug: Narrow implant
Normalized name: YARROW
Approvals — FDA: no, EMA: no, PMDA: no
Description: Narrow implant diameter
Study: 25393645
Drug: Abaloparatide 20
Normalized name: Abaloparatide 2000 MCG/1 ML Subcutaneous Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Abaloparatide 20 μg
Study: 25393645
Drug: Abaloparatide 40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Abaloparatide 40 μg
Study: 25393645
Drug: Teriparatide 20
Normalized name: TERIPARATIDE 200UNT/VIL INJ
Approvals — FDA: no, EMA: no, PMDA: no
Description: Teriparatide 20 μg
Study: 3914885
Drug: Intravaginal PGF2
Normalized name: Intravaginal contraceptives
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravaginal PGF2 alpha (40 mg in tylose gel)
Study: 27577237
Drug: PfAMA1-FVO vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PfAMA1-FVO vaccine (50 µg)
Study: 27577237
Drug: Control vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control vaccine (tetanus toxoid)
Study: 24388792
Drug: One-day bowel
Normalized name: Gel-One
Approvals — FDA: no, EMA: no, PMDA: no
Description: One-day bowel preparation (fiber-free diet and 3 L of polyethylene glycol on day 0)
Study: 24388792
Drug: Two-day bowel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two-day bowel preparation (liquid diet and 3 L of polyethylene glycol in the evening of day -1, and 1L of PEG in the early morning of day 0)
Study: 24388792
Drug: One-day bowel
Normalized name: Gel-One
Approvals — FDA: no, EMA: no, PMDA: no
Description: One-day bowel preparation
Study: 24388792
Drug: Two-day bowel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two-day bowel preparation
Study: 23176073
Drug: 1.5 mg
Normalized name: boron 1.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.5 mg pramipexole
Study: 10719133
Drug: Blood pressure
Normalized name: Blood Pressure Kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Blood pressure biofeedback treatment (BF) once a week for a total of four sessions
Study: 10719133
Drug: Blood pressure
Normalized name: Blood Pressure Kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Blood pressure biofeedback treatment (BF)
Study: 8646865
Drug: Fluticasone propionate
Normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Fluticasone propionate cream, 0.05%, twice-daily (BID) application
Study: 8646865
Drug: Fluticasone propionate
Normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Fluticasone propionate cream, 0.05%, once-daily (QD) application
Study: 1906692
Drug: Immediate intravenous
Normalized name: IR-3535
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate intravenous beta-blocker therapy
Study: 3994783
Drug: Ciprofibrate (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ciprofibrate (100 mg daily, single administration)
Study: 3994783
Drug: Fenofibrate (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fenofibrate (300 mg daily, 3 administrations)
Study: 3994783
Drug: Ciprofibrate (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ciprofibrate (100 or 200 mg/day after 9 months)
Study: 3994783
Drug: Fenofibrate (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fenofibrate (400 mg/day after 9 months)
Study: 22339105
Drug: Far infrared
Normalized name: Menthol/Methyl Salicylate 3%-0.5% Topical application Patch, Extended Release [GOLDEN SUNSHINE FAR INFRARED HOT HERBAL]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Far infrared rays (FIR) thermal therapy applied on acupoints ST37, ST38, ST39, ST40 from day 3 to day 5 post-surgery
Study: 18642381
Drug: Voice exercise
Approvals — FDA: no, EMA: no, PMDA: no
Description: Voice exercise therapy (VE)
Study: 16926331
Drug: Endovascular brachytherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endovascular brachytherapy (EBT) with an iridium 192 source, prescribed dose of 12 Gy at 3 mm from the source axis
Study: 9651260
Drug: Intravenous heroin
Normalized name: heroin
DrugBank: Diamorphine (DB01452)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous heroin
Study: 11041310
Drug: Oral opiates
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral opiates
Study: 11041310
Drug: Mixed regimens
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mixed regimens (intravenous heroin and oral opiates)
Study: 11041310
Drug: Alternative treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alternative treatments (methadone maintenance, detoxification)
Study: 1418021
Drug: Intraarticular injections
Normalized name: dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intraarticular injections of glycosaminoglycan polysulfate (GAGPS) plus basic conservative treatment
Study: 1418021
Drug: Physiologic saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physiologic saline injections plus basic conservative treatment
Study: 1418021
Drug: Basic conservative
Normalized name: Basic Fuchsin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Basic conservative treatment alone (6-week program of quadriceps muscle exercise, elimination of symptom-producing activities, and oral NSAIDs)
Study: 26602795
Drug: Both treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both treatments (EVLA and SFL/S)
Study: 20197703
Drug: Higher fasting
Normalized name: Fast Freeze
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher fasting insulin levels
Study: 17656271
Drug: Mepivacaine (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mepivacaine (30 mg in 1 mL saline)
Study: 17656271
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of Mepivacaine and Morphine (30 mg mepivacaine and 1 mg morphine in 1 mL saline)
Study: 17656271
Drug: Morphine (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine (1 mg in 1 mL saline)
Study: 17656271
Drug: Saline control
Normalized name: GLYCERIN 0.53 g in 1 mL CUTANEOUS INJECTION [Glycerol-Saline Control]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline control (1 mL saline)
Study: 7758179
Drug: Testosterone cypionate
Normalized name: Testosterone Cypionate
DrugBank: Testosterone cypionate (DB13943)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Testosterone cypionate 200 mg IM given twice, 2 weeks apart
Study: 2321713
Drug: Intramuscular administration
Normalized name: Japanese Encephalitis vaccine for intramuscular administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular administration of lytic cocktail (0.05 ml/kg, max 2.0 ml)
Study: 2321713
Drug: Rectal administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Rectal administration of lytic cocktail (0.07 ml/kg, max 2.8 ml)
Study: 6968567
Drug: ICI 35
Approvals — FDA: no, EMA: no, PMDA: no
Description: ICI 35 868, dose: 2 mg kg‐1, injected over 30 s
Study: 6968567
Drug: Althesin, dose:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Althesin, dose: 0.05 ml kg‐1, injected over 30 s
Study: 31940991
Drug: Paclitaxel-based chemotherapy
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Paclitaxel-based chemotherapy
Study: 31940991
Drug: Non-paclitaxel-based chemotherapy
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Non-paclitaxel-based chemotherapy
Study: 30732143
Drug: Interactive voice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interactive voice response system (IVRS) providing automatic calls in 3 categories: educational, medication adherence, and reminders.
Study: 9322987
Drug: Aspirin, 100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin, 100 mg/d, starting at 12 to 16 weeks of gestation, taken at time 1 (on awakening)
Study: 9322987
Drug: Aspirin, 100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin, 100 mg/d, starting at 12 to 16 weeks of gestation, taken at time 2 (8 hours after awakening)
Study: 9322987
Drug: Aspirin, 100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin, 100 mg/d, starting at 12 to 16 weeks of gestation, taken at time 3 (before bedtime)